NCT02338336 - A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions

Plantar Warts

Interventions

DRUG

Nowarta110

Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.

DRUG

Placebo

Matching placebo liquid for topic administration.

Trial Locations (1)

92648

Nowarta Biopharma Inc, Huntington Beach